 - DMT310 achieved a PGA score of 0 or 1 for the target lesion in 29.6 of patients at Week 8 - - DMT310 demonstrated a total PASI score of 0 or 1 for the target lesion in 25.9 of patients at Week 8 - - DMT310 demonstrated a 19.6 reduction from baseline in pruritus at Week 8 - - Phase 1b results support further investigation of DMT310 in psoriasis - SAN DIEGO, CA ACCESSWIRE October 18, 2021 Dermata Therapeutics, Inc. Dermata or the Company NASDAQ:DRMA, a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermatas lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea. 